Table 1.
Clinical Characteristics of Patients who received DLI
| Total | CML | AML+ | MDS | Lymphoma | Other Malignancies* | Non Malignancies | P-value | ||
|---|---|---|---|---|---|---|---|---|---|
| ALL | |||||||||
| Factors | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||
| Total N | 120 | 25 | 31 | 12 | 10 | 18 | 24 | ||
| Age (years) | <20 | 32(27%) | 0 | 3(10%) | 2(17%) | 1(10%) | 3(17%) | 23(96%) | <0.01 |
| 20-40 | 25(21%) | 13(52%) | 7(23%) | 1(8%) | 2(20%) | 1(6%) | 1(4%) | ||
| ≥40 | 63(53%) | 12(48%) | 21(68%) | 9(75%) | 7(70%) | 14(78%) | 0 | ||
| Sex | Male | 69(58%) | 11(44%) | 19(61%) | 5(42%) | 7(70%) | 13(72%) | 14(58%) | 0.36 |
| Female | 51(43%) | 14(56%) | 12(39%) | 7(58%) | 3(30%) | 5(28%) | 10(42%) | ||
| Year of DLI | 1990-1999 | 28(23%) | 18(72%) | 5(16%) | 3(25%) | 0 | 1(6%) | 1(4%) | <0.01 |
| 2000-2009 | 62(52%) | 5(20%) | 19(61%) | 5(42%) | 7(70%) | 12(67%) | 14(58%) | ||
| 2010-2013 | 30(25%) | 2(8%) | 7(23%) | 4(33%) | 3(30%) | 5(28%) | 9(38%) | ||
| Pre-DLI treatment | Chemotherapy | 37(31%) | 3(12%) | 19(61%) | 4(33%) | 7(70%) | 4(22%) | 0 | <0.01 |
| None | 83(69%) | 22(88%) | 12(39%) | 8(67%) | 3(30%) | 14(78%) | 24(100%) | ||
| Donor Type | HLA matched sibling | 83(69%) | 16(64%) | 25(81%) | 8(67%) | 7(70%) | 13(72%) | 14(58%) | 0.6 |
| Unrelated | 37(31%) | 9(36%) | 6(19%) | 4(33%) | 3(30%) | 5(28%) | 10(42%) | ||
| Dose of DLI (CD3/kg) | <1×107 | 27(23%) | 6(24%) | 6(19%) | 2(17%) | 0 | 0 | 13(54%) | <0.01 |
| 1×107-1×108 | 65(54%) | 14(56%) | 14(45%) | 7(58%) | 6(60%) | 13(72%) | 11(46%) | ||
| ≥1×108 | 28(23%) | 5(20%) | 11(36%) | 3(25%) | 4(40%) | 5(28%) | 0 | ||
| Time from HCT to DLI | < 200 days | 45(38%) | 3(12%) | 13(42%) | 6(50%) | 3(30%) | 7(39%) | 13(54%) | 0.05 |
| ≥ 200 days | 75(63%) | 22(88%) | 18(58%) | 6(50%) | 7(70%) | 11(61%) | 11(46%) | ||
*
Other malignancies include myeloproliferative disease (n= 3), multiple myeloma (n=5), plasma cell leukemia (n= 4), Juvenile CML (n= 3), chronic lymphocytic leukemia (n= 2), prolymphocytic leukemia (n= 1), and renal cell carcinoma (n= 1).